Hemoglobinopathies Market

The global Hemoglobinopathies market was valued at US$ 282.5 million in 2022 and is projected to reach US$ 379.4 million by 2029, at a CAGR of 4.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Hemoglobinopathy or Hemoglobinopathies is the medical term for a group of blood disorders and diseases that affect red blood cells. It can be a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule.
Hemoglobinopathies Market aims to provide a comprehensive presentation of the global market for Hemoglobinopathies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemoglobinopathies. Hemoglobinopathies Market contains market size and forecasts of Hemoglobinopathies in global, including the following market information:

• Global Hemoglobinopathies Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global top five companies in 2022 (%)

Increasing cases of hemoglobinopathies, especially in regions such as Southeast Asia and Africa, is one of the major growth drivers.
We surveyed the Hemoglobinopathies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

• Blood Transfusion
• Iron Chelation Therapy
• Bone Marrow Transplant
• Others

• Blood Testing
• Genetic Testing
• Pre-Implantation Genetic Diagnosis (PGD)
• Others

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

• Key companies Hemoglobinopathies revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Hemoglobinopathies revenues share in global market, 2022 (%)

key players include:

• Gamida Cell
• Alnylam Pharmaceuticals
• Sanofi
• Sangamo Therapeutics Inc.
• Global Blood Therapeutics
• Bluebird Bio
• Emmaus Life Sciences Inc.
• Prolong Pharmaceuticals
• Celgene Corporation
• Outline of Major Chapters:
• Chapter 1: Introduces the definition of Hemoglobinopathies, market overview.
• Chapter 2: Global Hemoglobinopathies market size in revenue.
• Chapter 3: Detailed analysis of Hemoglobinopathies company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
• Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
• Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
• Chapter 6: Sales of Hemoglobinopathies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
• Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
• Chapter 8: The main points and conclusions of the report.